Sigma Planning Corp Reduces Stake in uniQure (NASDAQ:QURE)

Sigma Planning Corp lessened its holdings in shares of uniQure (NASDAQ:QURE) by 3.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 46,745 shares of the biotechnology company’s stock after selling 1,500 shares during the period. Sigma Planning Corp owned 0.10% of uniQure worth $826,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in QURE. abrdn plc raised its holdings in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of uniQure in the 3rd quarter valued at $7,360,000. Point72 Asset Management L.P. raised its stake in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after acquiring an additional 752,889 shares in the last quarter. FMR LLC raised its stake in uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after acquiring an additional 346,274 shares in the last quarter. Finally, Privium Fund Management B.V. lifted its position in uniQure by 16.3% in the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after acquiring an additional 104,500 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.74% of the company’s stock.

Wall Street Analyst Weigh In

QURE has been the topic of several research reports. Stifel Nicolaus raised their price objective on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. HC Wainwright raised their price target on uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. The Goldman Sachs Group boosted their price objective on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Leerink Partners raised their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Finally, Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $40.00.

uniQure Price Performance

Shares of NASDAQ QURE opened at $10.99 on Wednesday. The stock has a fifty day moving average price of $15.38 and a 200 day moving average price of $9.69. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The company has a market cap of $535.69 million, a PE ratio of -2.22 and a beta of 0.39.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.